This paper is only available as a PDF. To read, Please Download here.
Abstract
Functional status in schizophrenia depends in part on cognitive function. Newer antipsychotics,
such as risperidone, produce better cognitive function in patients with schizophrenia
than do conventional neuroleptics, which implies that the indirect costs of the illness
will be less in patients treated with risperidone. A robust decision-analytic model
of schizophrenia suggests that the overall cost of treating a patient with risperidone
is $11,772.00 per year compared with $13,622.00 per year for haloperidol and that
the cost per response is even more favorable toward risperidone—$14,599.00 versus
$23,040.00. This model supports the results of naturalistic trials in which risperidone
produced better outcomes than did conventional neuroleptics. Overall, the use of the
more effective, better tolerated newer antipsychotics should reduce the cost to society
of schizophrenia and improve patients' quality of life.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Diagnosis and classification of schizophrenia.Schizophr Bull. 1993; 19: 199-214
- Schizoprenia.NEJM. 1994; 330: 681-690
- 4th ed. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, DC1994
- Schizophrenia: The characteristic symptoms.Schizophr Bull. 1991; 17: 274-279
- Descriptive psychopathology.in: Hirsch SR Weinberger DR Schizophrenia. Blackwell, Oxford, England1995
- Cognitive deficits in schizophrenia.Psychiatr Clin North Am. 1993; 16: 295-311
- New medications for the schizophrenics.Med J Aust. 1994; 160: 53-54
- Schizophrenia.Aust J Hosp Pharm. 1996; 26: 93-96
- Schizophrenia: Treatment outcomes research—editors' introduction.Schizophr Bull. 1995; 21: 561-566
- The costs of schizophrenia. Assessing the burden.Psychiatr Clin North Am. 1993; 16: 413-423
- Health economic considerations in the treatment of schizophrenia.8th Congress of the European College of Neuropsychopharmacology. 3041995; (Presented at the) (Venice, Italy)
- Cost-effectiveness studies in the treatment of schizophrenia: A review.Schizophr Bull. 1991; 17: 453-459
- Long-term community care through an assertive continuous treatment team.in: Tamminga CA Schulz SC Schizophrenia Research. Raven Press, New York1991: 239-246
- Dimensions of outcome with clozapine.Br J Psychiatry. 1992; 160: 46-53
- Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia.Am J Psychiatry. 1993; 150: 1630-1638
- Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.J Clin Psychiatry. 1994; 55: 5-12
- A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.J Clin Psychopharmacol. 1993; 13: 25-40
- Risperidone in the treatment of schizophrenia.Am J Psychiatry. 1994; 151: 825-835
- Economic evaluation of mental health services.Curr Opin Psychiatry. 1995; 8: 122-125
- Assessment of the costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom.Br J Psychiatry. 1993; 162: 38-42
- Efficacy, safety and cost effectiveness of risperidone versus haloperidol. I. Meta-analysis. Janssen-Cilag, Beerse, Belgium1995 (Data on file)
- Efficacy, safety and cost effectiveness of risperidone versus haloperidol. II. Cost-effectiveness. Janssen-Cilag, Beerse, Belgium1995 (Data on file)
- Reduction of hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study.Clin Ther. 1993; 15: 917-926
- Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia.Clin Ther. 1995; 17: 402-412
- Naturalistic outcome of risperidone treatment in an academic state hospital setting.seventh annual meeting of the New York Office of Mental Health. 791994; (Presented at the) (Albany, New York)
- Cost and benefit analysis for clozapine and risperidone.149th annual meeting of the American Psychiatric Association. 491996; (Presented at the) (New York, New York)
- Health Status and Health Policy: Allocating Resources to Health Care. Oxford University Press, New York, NY1993
- Assessing health related quality of life outcomes of drug treatments for psychiatric disorders.CNS Drugs. 1994; 1: 465-476
- Quality of life, health status and clinical research.Med Care. 1989; 27 (Suppl 3): S148-S156
- Subjective response to neuroleptics and the quality of life: Implications for treatment outcome.Acta Psychiatr Scand. 1994; 89: 27-32
- A neuropsychiatric approach to impairment of goal-directed behaviour.149th annual meeting of the American Psychiatric Association. 491996; (Presented at the) (New York, New York)
- Neurocognitive deficits in schizophrenia.in: Hirsch SR Weinberger DR Schizophrenia. Blackwell, Oxford, England1995: 146-162
- Neuroanatomy, measurement and clinical significance of the executive cognitive functions.149th annual meeting of the American Psychiatric Association. 491996; (Presented at the) (New York, New York)
- Physiologic significance of dorsolateral prefrontal cortex in schizophrenia. I: Regional cerebral blood flow evidence.Arch Gen Psychiatry. 1986; 43: 114-124
- Effects of clozapine on cognitive function in schizophrenia.J Clin Psychiatry. 1994; 55: 82-87
- The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.Br J Psychiatry. 1993; 162: 43-48
Goldberg TE, Daniel DG, Pickar D, et al. Differential effects of risperidone and conventional neuroleptics on neurocognition: A pilot study. Abstract.
- Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.Eur Neuropsychopharmacol. 1996; 6 (Suppl 2): S2 13-S2 20
- Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.Am J Psychiatry. 1993; 150: 1630-1638
Article info
Identification
Copyright
© 1997 Published by Elsevier Inc.
